5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain
| Autor: | Emanuel Meller, Jingyuan Chen, Changpeng Shen |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Agonist medicine.medical_specialty medicine.drug_class p38 mitogen-activated protein kinases Rats Sprague-Dawley Internal medicine medicine Animals Phosphorylation Receptor Protein kinase A Mitogen-Activated Protein Kinase 1 Pharmacology 8-Hydroxy-2-(di-n-propylamino)tetralin Mitogen-Activated Protein Kinase 3 Dose-Response Relationship Drug biology MAP kinase kinase kinase Kinase Phosphotransferases Brain Molecular biology Rats Endocrinology Receptors Serotonin Mitogen-activated protein kinase biology.protein Mitogen-Activated Protein Kinases Signal transduction Receptors Serotonin 5-HT1 |
| Zdroj: | European Journal of Pharmacology. 452:155-162 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/s0014-2999(02)02297-5 |
| Popis: | Mitogen-activated protein kinases (MAPKs), a family of signal transduction mediators important in a host of cellular activities, include the extracellular signal-regulated kinases Erk1 and Erk2. We determined whether 5-HT(1A) receptors activate Erk1/2 in rat brain in vivo, as they do in recombinant cell lines. In contrast to the effect in cells, the 5-HT(1A) receptor agonist 8-hydroxy-N,N-diproylaminotetralin (8-OH-DPAT) dose- and time-dependently decreased basal levels of phosphorylated Erk1/2 (phospho-Erk1/2) in rat hippocampus (ED(50) approximately 0.1 mg/kg, maximum approximately 90%) without altering total Erk1/2. The effects were kinase-specific, as 8-OH-DPAT did not modify phosphorylated or total levels of the MAPKs c-Jun-N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 MAPK. Moreover, 8-OH-DPAT did not modify phospho-Erk1/2 in striatum or frontal cortex. The effect of 8-OH-DPAT was blocked by pretreatment with the selective 5-HT(1A) receptor antagonists N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY 100635), 1-(2-methoxyphenyl)-4-(4-[2-phthalimido]butyl)piperazine (NAN-190) and 4-fluoro-N-(2-[4-(2-methoxyphenyl)1-piperazinyl]ethyl)-N-(2-pyridinyl)benzamide dihydrochloride (p-MPPF), but not by the weak partial agonist/antagonist 8-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro(4.5)decane-7,9-dione dihydrochloride (BMY 7378). Other 5-HT(1A) receptor agonists (buspirone, gepirone and ipsapirone) also reduced phospho-Erk1/2 levels in hippocampus. 8-OH-DPAT also reduced the levels of the upstream activator of Erk1/2, phosphorylated extracellular signal-regulated kinase kinase (phospho-MEK1/2), and at least one potential downstream target, the nuclear transcription factor phospho-Elk-1. The region- and kinase-specific effects suggest that the Erk1/2 signal transduction cascade is likely an important differential mediator of 5-HT(1A) receptor-regulated events in the central nervous system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect